This activity is sponsored by Bausch + Lomb.
This activity is sponsored by Bausch + Lomb.
Please see Indication and Important Safety Information below.
Douglas A. Katsev, MD, is a cornea specialist at the Sansum Clinic in Santa Barbara, Calif. Dr. Katsev is a paid consultant for Bausch + Lomb.
Carlos Buznego, MD, practices at the Center for Excellence in Eye Care in Miami. Dr. Buznego is a member of the Ocular Surgery News Editorial Board. Dr. Buznego is a paid consultant for Bausch + Lomb.
Mitchell A. Jackson, MD, is founder/medical director of Jacksoneye in Lake Villa, Ill. Dr. Jackson is a member of the Ocular Surgery News Editorial Board. Dr. Jackson is a paid consultant for Bausch + Lomb.
Cynthia Matossian, MD, FACS, is founder of Matossian Eye Associates in Doylestown, Pa. Dr. Matossian is a paid consultant for Bausch + Lomb.
Rajesh L. Rajpal, MD, is founder of See Clearly Vision Group and is a clinical faculty member at Georgetown University in Washington, D.C. Dr. Rajpal is a paid consultant for Bausch + Lomb.
Kenneth J. Rosenthal, MD, is a faculty member at the New York Eye and Ear Infirmary of Mt. Sinai in Manhattan, N.Y. Dr. Rosenthal is a member of the Ocular Surgery News Editorial Board and is a paid consultant for Bausch + Lomb.
Inder Paul Singh, MD, is president of the Eye Centers of Racine and Kenosha in Wisconsin. Dr. Singh is a paid consultant of Bausch + Lomb.
P. Dee Stephenson, MD, FACS, is founder of Stephenson Eye Associates in Venice, Fla. Dr. Stephenson is a paid consultant for Bausch + Lomb.
John R. Wittpenn, MD, is partner at Ophthalmic Consultants of Long Island and associate clinical professor of ophthalmology, State University at Stony Brook. Dr. Wittpenn is a paid consultant for Bausch + Lomb.
The goal of cataract surgery is to improve vision for patients, so ophthalmologists need more than just a quality IOL and the latest surgical tools on hand. For patients who have inflammation and/or pain after cataract surgery, surgeons should prescribe an NSAID that inhibits cyclooxygenase enzymes and also penetrates the cornea.
OCULAR SURGERY NEWS, with the support of Bausch + Lomb, gathered leading ophthalmologists during the 2015 American Society of Cataract and Refractive Surgery annual meeting to discuss the use of PROLENSA® (bromfenac ophthalmic solution) 0.07% (Bausch + Lomb) in terms of corneal penetration, potency, anti-inflammatory efficacy and pain reduction. Topics include the performance of Prolensa in clinical trials, the benefits of using the product in relationship to its cost and tactics for increasing pharmacy fills and decreasing callbacks.
I thank the faculty members for their participation, as well as Bausch + Lomb for sponsoring this Ocular Surgery News supplement. For more educational materials on this topic, visit Healio.com/Ophthalmology/Education-Lab.
Richard L. Lindstrom, MD
Chief Medical Editor
OCULAR SURGERY NEWS
PROLENSA® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
PROLENSA® contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs.
There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening.
Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
PROLENSA®, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA®.
The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision.
Please click here (PDF) to view full PROLENSA® prescribing information.
page 1 of 11
Please click on Next tab to advance through activity.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.